Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SNPS
stocks logo

SNPS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.24B
+36.63%
2.879
-15.32%
2.42B
+66%
3.398
+12.14%
2.29B
+42.57%
3.162
-13.85%
Estimates Revision
The market is revising Downward the revenue expectations for Synopsys, Inc. (SNPS) for FY2025, with the revenue forecasts being adjusted by -5.48% over the past three months. During the same period, the stock price has changed by -22.96%.
Revenue Estimates for FY2025
Revise Downward
down Image
-5.48%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-11.92%
In Past 3 Month
Stock Price
Go Down
down Image
-22.96%
In Past 3 Month
Wall Street analysts forecast SNPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNPS is 559.38 USD with a low forecast of 425.00 USD and a high forecast of 630.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast SNPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNPS is 559.38 USD with a low forecast of 425.00 USD and a high forecast of 630.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
3 Hold
2 Sell
Moderate Buy
Current: 463.740
sliders
Low
425.00
Averages
559.38
High
630.00
Current: 463.740
sliders
Low
425.00
Averages
559.38
High
630.00
Wells Fargo
Joe Quatrochi
Equal Weight
downgrade
$550 -> $445
2025-11-25
Reason
Wells Fargo
Joe Quatrochi
Price Target
$550 -> $445
2025-11-25
downgrade
Equal Weight
Reason
Wells Fargo analyst Joe Quatrochi lowered the firm's price target on Synopsys to $445 from $550 and keeps an Equal Weight rating on the shares. The firm notes shares returning to post Q3 EPS lows creates an easier setup. However, Wells is lowering its estimates and expects a conservative initial 2026 guide in line with the Street.
Citi
Kelsey Chia
initiated
$580
2025-11-24
Reason
Citi
Kelsey Chia
Price Target
$580
2025-11-24
initiated
Reason
Citi analyst Kelsey Chia initiated coverage of Synopsys with a Buy rating and $580 price target. The firm believes the electronic design automation market is "emerging as the backbone" of the next growth phase of artificial intelligence. The sector is brining intelligence from software to the physical world, which should drive double-digit revenue growth with 40% operating margins, the analyst tells investors in a research note. Citi sees a favorable fundamental setup for Synopsys.
Mizuho
Outperform -> NULL
downgrade
$700 -> $600
2025-09-11
Reason
Mizuho
Price Target
$700 -> $600
2025-09-11
downgrade
Outperform -> NULL
Reason
Mizuho lowered the firm's price target on Synopsys to $600 from $700 and keeps an Outperform rating on the shares. The company's fiscal Q3 results were mixed as strength in design automation was offset by weakness in the intellectual property segment, the analyst tells investors in a research note. The firm says that while fiscal 2026 is a transition year for Synopsys with the Ansys acquisition and IP roadmap reset, it remains confident in management's ability to sustain growth in simulation while focusing on profitability and debt reduction. The stock's 36% selloff yesterday is an overreaction and presents a buying opportunity, contends Mizuho.
Baird
Outperform -> Neutral
downgrade
$670 -> $535
2025-09-10
Reason
Baird
Price Target
$670 -> $535
2025-09-10
downgrade
Outperform -> Neutral
Reason
Baird downgraded Synopsys to Neutral from Outperform with a price target of $535, down from $670. The company's fiscal Q4 outlook came in well below expectations after de-risking the intellectual property forecast, the analyst tells investors in a research note. The firm expects the company's IP growth in fiscal 2026 to be "muted." The Q4 report and lack of forward visibility create an overhang on the shares that will likely take time to clear, contends Baird.
BofA
Buy
to
Underperform
downgrade
$625 -> $525
2025-09-10
Reason
BofA
Price Target
$625 -> $525
2025-09-10
downgrade
Buy
to
Underperform
Reason
BofA downgraded Synopsys to Underperform from Buy with a price target of $525, down from $625.
KeyBanc
KeyBanc
Overweight
downgrade
$660 -> $590
2025-09-10
Reason
KeyBanc
KeyBanc
Price Target
$660 -> $590
2025-09-10
downgrade
Overweight
Reason
KeyBanc lowered the firm's price target on Synopsys to $590 from $660 and keeps an Overweight rating on the shares. Synopsys delivered a messy and underwhelming Q3 print. Based on its assumptions, the firm believes the company is cutting FY25 guidance by about $480M, which seems overly conservative. While one could sympathize the IP headwinds are largely out of Synopsys' control, KeyBanc is frustrated by the lack of disclosures on Ansys, making it hard to decipher the good from the bad in an already complicated story. With heightened execution risk, the firm is lowering its price target but remains positive on secular EDA tailwinds and the company's opportunities in 3D-IC, AI, margin expansion prospects.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Synopsys Inc (SNPS.O) is 36.01, compared to its 5-year average forward P/E of 37.15. For a more detailed relative valuation and DCF analysis to assess Synopsys Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
37.15
Current PE
36.01
Overvalued PE
41.76
Undervalued PE
32.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
27.09
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
30.36
Undervalued EV/EBITDA
23.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.50
Current PS
0.00
Overvalued PS
12.11
Undervalued PS
8.90
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 427.09% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SNPS News & Events

Events Timeline

(ET)
2025-12-01
14:40:00
Nvidia Invests $2B in Synopsys, Analyst Reiterates Outperform Rating
select
2025-12-01
12:11:00
Major Averages Decline as Investors Await Economic Data and Powell's Speech
select
link
2025-12-01
10:00:00
Synopsys (SNPS) Leads Liquid Options Gainers with 18.39% Surge
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
05:21 AMGlobenewswire
Synopsys, Inc. Faces Class Action Lawsuit Over Alleged Securities Fraud
  • Class Action Initiation: Levi & Korsinsky has filed a class action lawsuit against Synopsys, aiming to recover losses for investors affected between December 2024 and September 2025, highlighting significant investor concerns regarding the company's financial transparency.
  • Allegations Overview: The lawsuit claims that the company's excessive focus on AI customer customization has deteriorated the economics of its Design IP business, negatively impacting financial results and indicating potential flaws in strategic decision-making.
  • Investor Rights Protection: Affected investors must apply by December 30, 2025, to be appointed as lead plaintiffs to participate in potential recovery, demonstrating the legal avenues available for investor protection.
  • Law Firm Background: With 20 years of experience in securities litigation, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders, showcasing its expertise and successful track record in complex securities cases.
[object Object]
Preview
7.0
01:22 AMGlobenewswire
Cytokinetics Faces Shareholder Claims Over Executive Misconduct
  • Shareholder Claims Investigation: Grabar Law Office is investigating whether Cytokinetics' executives breached their fiduciary duties, allowing shareholders who purchased shares before December 27, 2023, to seek corporate reforms and fund recovery.
  • FDA Approval Delay: On May 1, 2025, Cytokinetics announced that the FDA extended the review date for aficamten's NDA from September 26, 2025, to December 26, 2025, due to the omission of a Risk Evaluation and Mitigation Strategy in the initial filing, causing significant shareholder harm.
  • False Statement Allegations: Executives are accused of misleading investors by stating on March 10, 2025, that the FDA would not convene an advisory committee meeting, leading to incorrect assessments of the company's prospects and negatively impacting stock prices.
  • Severe Market Reaction: These allegations have left Cytokinetics' shareholders facing potential financial losses, severely undermining market confidence in the company's future and possibly leading to further declines in stock value.
[object Object]
Preview
7.0
01:21 AMGlobenewswire
Avantor and Others Face Class Action Lawsuits; Investors Must Note Deadlines
  • Class Action Alert: Avantor, Inc. (NYSE:AVTR) faces a class action lawsuit for failing to disclose weakened competitive positioning during the period from March 5, 2024, to October 28, 2025, with a lead plaintiff deadline of December 29, 2025, potentially impacting stock price and investor confidence.
  • Competitive Pressure Revealed: Synopsys, Inc. (NASDAQ:SNPS) is accused of not disclosing that its increased focus on AI customers negatively affected its Design IP business from December 4, 2024, to September 9, 2025, with a lead plaintiff deadline of December 30, 2025, reflecting significant market challenges.
  • Growth Prospects Questioned: CarMax, Inc. (NYSE:KMX) is alleged to have overstated growth prospects during the period from June 20, 2025, to November 5, 2025, with a lead plaintiff deadline of January 2, 2026, which may lead to diminished market confidence in future performance.
  • Demand Shortfall Issues: Inspire Medical Systems, Inc. (NYSE:INSP) faces allegations of failing to disclose poor demand for its new treatment from August 6, 2024, to August 4, 2025, with a lead plaintiff deadline of January 5, 2026, indicating significant challenges in product rollout.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Synopsys Inc (SNPS) stock price today?

The current price of SNPS is 463.74 USD — it has decreased -0.58 % in the last trading day.

arrow icon

What is Synopsys Inc (SNPS)'s business?

Synopsys, Inc. is engaged in providing engineering solutions from silicon to systems, enabling customers to innovate artificial intelligence (AI)-powered products. It delivers silicon design, intellectual property (IP), simulation and analysis solutions, and design services. It supplies mission-critical electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). Its Design Automation segment includes its advanced silicon design, verification products and services and system integration products. This segment also includes digital, custom and field programmable gate arrays, integrated circuit design software, verification software and hardware products, system integration products and services, and manufacturing software products. Its Design IP segment includes its interface, foundation, security, and embedded processor IP, IP subsystems, and IP implementation services that serve companies in the semiconductor and electronics industries.

arrow icon

What is the price predicton of SNPS Stock?

Wall Street analysts forecast SNPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNPS is 559.38 USD with a low forecast of 425.00 USD and a high forecast of 630.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Synopsys Inc (SNPS)'s revenue for the last quarter?

Synopsys Inc revenue for the last quarter amounts to 1.74B USD, increased 14.03 % YoY.

arrow icon

What is Synopsys Inc (SNPS)'s earnings per share (EPS) for the last quarter?

Synopsys Inc. EPS for the last quarter amounts to 1.50 USD, decreased -42.53 % YoY.

arrow icon

What changes have occurred in the market's expectations for Synopsys Inc (SNPS)'s fundamentals?

The market is revising Downward the revenue expectations for Synopsys, Inc. (SNPS) for FY2025, with the revenue forecasts being adjusted by -5.48% over the past three months. During the same period, the stock price has changed by -22.96%.
arrow icon

How many employees does Synopsys Inc (SNPS). have?

Synopsys Inc (SNPS) has 20000 emplpoyees as of December 05 2025.

arrow icon

What is Synopsys Inc (SNPS) market cap?

Today SNPS has the market capitalization of 86.14B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free